The estimated Net Worth of Robert J Ready is at least $21.2 millió dollars as of 11 March 2015. Robert Ready owns over 10,000 units of Meridian Bioscience stock worth over $20,187,861 and over the last 21 years Robert sold VIVO stock worth over $999,364.
Robert has made over 13 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert sold 10,000 units of VIVO stock worth $77,000 on 11 March 2015.
The largest trade Robert's ever made was selling 28,250 units of Meridian Bioscience stock on 4 February 2015 worth over $207,638. On average, Robert trades about 2,203 units every 25 days since 2003. As of 11 March 2015 Robert still owns at least 594,285 units of Meridian Bioscience stock.
You can see the complete history of Robert Ready stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 10000 ALLIANCE RD, LSI INDUSTRIES INC, CINCINNATI, OH, 45242.
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny és John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian Bioscience executives and other stock owners filed with the SEC include: